DP
REGN icon

DDD Partners’s Regeneron Pharmaceuticals REGN Stock Holding History

DDD Partners’s Portfolio REGN Stock Details REGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$20.1M Buy
32,303
+5,383
+20% +$3.66M 1.26% 29
2026
Q1 		$20.8M Buy
26,920
+2,846
+12% +$2.18M 1.43% 13
2025
Q4 		$18.6M Buy
24,074
+2,713
+13% +$1.84M 1.18% 26
2025
Q3 		$12M Buy
21,361
+865
+4% +$489K 0.76% 39
2025
Q2 		$10.8M Buy
+20,496
New +$11.4M 1.15% 33

Other funds holding REGN

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Dodge & Cox
Dodge & Cox San Francisco, California $191B AUM 17.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Nuveen
Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

DDD Partners's REGN Position: Q2 2026 in Review

DDD Partners increased its Regeneron Pharmaceuticals (REGN) stake by 20% in Q2 2026, buying an estimated $3.66M and bringing the position to 32,303 shares worth $20.1M. The position accounts for 1.26% of the portfolio, ranked #29.

DDD Partners first reported a position in REGN in Q2 2025 and has held it in 5 quarters since. The position peaked at $20.8M in Q1 2026. 1,336 funds tracked by Wall St. Rank hold REGN as of Q2 2026.

  • DDD Partners held 32,303 shares of Regeneron Pharmaceuticals worth $20.1M as of Q2 2026.
  • DDD Partners bought 5,383 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $3.66M.
  • Regeneron Pharmaceuticals made up 1.26% of DDD Partners's portfolio in Q2 2026, its #29 holding.
  • DDD Partners first reported a position in Regeneron Pharmaceuticals in Q2 2025 and has held it in 5 quarters since.
  • DDD Partners's Regeneron Pharmaceuticals position peaked at $20.8M in Q1 2026.
  • 1,336 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.

Based on DDD Partners's 13F filing for Q2 2026, filed 5 Aug 2026.